Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shanghai Menon Animal Nutrition Technology
301156
5
Nanjing Railway New Technology
301016
US Stock MarketDetailed Quotes
DBVT DBV Technologies
- 6.500
- -1.360-17.30%
Close Apr 4 16:00 ET
- 6.500
- 0.0000.00%
Post 16:55 ET
133.36MMarket Cap-1.11P/E (TTM)
7.480High6.000Low143.56KVolume7.230Open7.860Pre Close989.72KTurnover1.72%Turnover RatioLossP/E (Static)20.52MShares8.50052wk High4.87P/B54.23MFloat Cap2.20552wk Low--Dividend TTM8.34MShs Float505.700Historical High--Div YieldTTM18.83%Amplitude2.200Historical Low6.894Avg Price1Lot Size
About DBV Technologies Company
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.
Company Profile
SymbolDBVT
Company NameDBV Technologies
Listing DateOct 22, 2014
Issue Price21.64
Founded2002
CEOMr. Daniel Tasse
MarketNASDAQ
Employees104
Securities TypeDR
ADS Ratio1.0 : 5.0
Fiscal Year Ends12-31
Address107 avenue de la Republique
CityChatillon
ProvinceHF
CountryFrance
Zip Code92320
Phone33-1-55-42-78-78
Company Executives
- Name
- Position
- Salary
- Daniel Tasse
- Director and Chief Executive Officer
- 2.40M
- Virginie Boucinha
- Chief Financial Officer and Principal Accounting Officer
- 234.63K
- Dr. Pharis Mohideen, M.D.
- Chief Medical Officer
- 1.28M
- Michel De Rosen
- Non-Executive Chairman of the Board
- 10.81K
- Mailys Ferrere
- Independent Director
- --
- Julie O'Neill
- Independent Director
- 113.54K
- Daniele Guyot-Caparros
- Independent Director
- 118.94K
- Timothy E. Morris
- Independent Director
- 113.54K
- Michael J. Goller
- Independent Director
- 113.54K
- Daniel B. Soland
- Independent Director
- 113.54K
- Dr. Ravi Madduri Rao
- Independent Director
- 113.54K
- Dr. Adora Ndu, Pharm.D.
- Independent Director
- 113.54K
Market Insights
Discussing
Chinese stock earnings surge: Will profit sustain the rally?
1. Which sectors are likely to be market highlights this season? 2. With the government's emphasis on technological innovation and sustaina
Moomoo News Global
Mar 4 23:26
China's Two Sessions: Key Takeaways on Stock Price Movements Before and After the Meetings
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
